Role of CD47 in hematologic malignancies.
10.7534/j.issn.1009-2137.2013.06.050
- Author:
Guo-Hong SU
1
;
Yu-Lei ZHAO
2
Author Information
1. The Second Department of Hematology, Cangzhou Central Hospital, Cangzhou 061000, Hebei Province, China. E-mail:czshg009@163.com.
2. The Second Department of Hematology, Cangzhou Central Hospital, Cangzhou 061000, Hebei Province, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antigens, Differentiation;
metabolism;
CD47 Antigen;
metabolism;
Hematologic Neoplasms;
metabolism;
Humans;
Receptors, Immunologic;
metabolism;
Signal Transduction
- From:
Journal of Experimental Hematology
2013;21(6):1631-1634
- CountryChina
- Language:Chinese
-
Abstract:
CD47 is a ubiquitously expressed transmembrane glycoprotein on surface of many cells. Through its interaction with integrin, signal regulatory protein alpha (SIRPα) and thrombin sensitive protein-1 (TSP-1), it plays important roles in various immunological processes including inflammatory response, immune response and tumor immunity. Recently, it has been found that CD47 interacts with SIRPα expressed on phagocytic cells, which transfers a negative signal when being activated. By the mechanisms described above, CD47-SIRPα signal complex is involved in the pathogenesis of hematological diseases and might provide some informations for the therapy of patients. This review focuses on the structure and immunoregulatory functions of CD47, the mechanism of CD47 in tumor therapy, the CD47 and hematologic malignancies including acute leukemia, B-cell lymphoma and multiple myeloma, as well as CD47 and hematopoietic stem cell transplantation.
